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ABSTRACT
Background: In this study, our aim was to identify molecular aberrations 
predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. 
Methods: To generate hypotheses about potential markers for sensitivity to 
mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. 
Subsequently, a multicenter study was conducted. Patients with advanced solid 
tumors lacking standard of care treatment options were included and underwent 
a pre-treatment tumor biopsy to enable DNA sequencing of 1,977 genes, derive 
copy number profiles and determine activation status of pS6 and pERK. Treatment 
benefit was determined according to TTP ratio and RECIST. We tested for associations 
between treatment benefit and single molecular aberrations, clusters of aberrations 
and pathway perturbation. 
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INTRODUCTION
The introduction of targeted therapy has been 
accompanied by an intensive search for biomarkers 
to select patients for treatment. The identification of 
companion diagnostics may improve treatment outcomes 
and cost-effectiveness of increasingly expensive oncolytic 
drugs. Several powerful biomarker-drug combinations 
have been introduced in the clinic, such as crizotinib in 
ALK mutant lung cancer and vemurafenib in BRAF V600E 
mutant melanoma [1, 2]. For these treatments, evident 
tumor regression can be observed in selected populations. 
However, for drugs that induce disease stabilization, 
such as everolimus, it is more difficult to determine 
treatment benefit. Everolimus is an orally administered 
drug with proven efficacy in advanced clear cell renal cell 
carcinoma, neuroendocrine tumors and breast cancer [3-6]. 
Everolimus inhibits the mammalian Target of Rapamycin 
(mTOR) pathway and its downstream substrates, S6K 
and 4EBP1, which promote cell growth, proliferation 
and survival [7]. mTOR can be activated by upstream 
pathways such as the MAPK pathway and the AKT/PI3K 
pathway [7]. Previous studies have described several 
genetic aberrations that might be predictive for response to 
mTOR inhibition such as mutations in or loss of PIK3CA, 
PTEN, TSC and KRAS [8-22]. 
These genetic aberrations in the mTOR pathway 
and its interconnected pathways are present across many 
different tumor types (COSMIC database). It is therefore 
reasonable to believe that patients with other tumor types 
harboring the proper molecular profile might also benefit 
from treatment [21, 23]. Unfortunately, despite extensive 
knowledge on the mechanism of action of everolimus, 
no tissue broad biomarkers have yet been identified and 
clinically validated.
To address this issue, we revised genomic profiles 
and drug sensitivity of 835 cell lines to generate hypothesis 
about potential biomarkers, and conducted a prospective 
biomarker identification study for everolimus. This study 
was conducted by the Center for Personalized Cancer 
Treatment (www.cpct.nl), a large consortium of hospitals 
in the Netherlands devoted to personalized medicine.
RESULTS
Exploration of cell line data
The GDSC1000 cell line data from the Sanger 
Institute was used to search for potential markers for 
treatment sensitivity. As everolimus was not screened, 
we used the rapamycin analog temsirolimus as a proxy. 
IC50 values for temsirolimus were available for 835 cell 
lines, and sensitivity differed significantly between tumor 
types (p < 0.001; ANOVA). Specifically, non-small cell 
lung cancer (NSCLC), neuroblastoma, pancreatic and 
colon tumor cell lines were in general more resistant than 
e.g. kidney and bladder tumors (Supplementary Figure 
1). After selecting only solid tumors and correcting for 
tissue of origin, the elastic net analysis identified a small 
number of genetic aberrations that could be associated 
with response: PTEN mutations, FGFR2 mutations and 
CDKN2A loss were associated with increased sensitivity 
(Table 1). Gains in CCNE1 and ERCC5, as well as 
mutations in RB1, HGF, SOX9 and CIC were associated 
with temsirolimus resistance (Table 1). The strongest 
effect was seen for CCNE1 gain and FGFR2 mutations. 
Gain of CCNE1 was observed in 48 cell lines including 
breast (10/42) and NSCLC (11/100). Only within breast 
cancer cell lines, was CCNE1 gain alone also associated 
with temsirolimus resistance (P = 0.010; one-tailed t-test). 
FGFR2 mutations were only observed in eight cell lines, 
distributed over seven tumor types. 
Next, we focused on genes in the mTOR pathway or 
genes previously reported in association with sensitivity 
to mTOR inhibition. In our model including all tumor 
types, both PIK3CA and PTEN mutations were associated 
with increased sensitivity (P = 0.041 and P = 0.016, 
respectively; Wald test) (Table 1). PIK3CA mutations 
were most common in breast, NSCLC, ovarian, stomach, 
colorectal and aerodigestive tract tumor cell lines. PTEN 
mutations were also frequently observed in endometrial 
tumors. Within those subtypes, PIK3CA mutations were 
only associated with temsirolimus sensitivity in tumor 
cells from the aerodigestive tract (P = 0.014; one-tailed 
t-test) and cervical tumor cell lines (P = 0.023), but no 
such association could be seen for PIK3CA mutation 
Results: Cell line screens indicated several genes, such as PTEN (P = 0.016; 
Wald test), to be associated with sensitivity to mTOR inhibition. Subsequently 73 
patients were included, of which 59 started treatment with everolimus. Response and 
molecular data were available from 43 patients. PTEN aberrations, i.e. copy number 
loss or mutation, were associated with treatment benefit (P = 0.046; Fisher’s exact 
test). 
Conclusion: Loss-of-function aberrations in PTEN potentially represent a tumor 
type agnostic biomarker for benefit from everolimus and warrants further confirmation 
in subsequent studies.
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status in breast cancer (P = 0.411), and an opposite effect 
was observed in endometrial cancer (P = 0.053). PTEN 
mutations were significantly associated with response in 
ovarian (P = 0.0211) and endometrial tumor cells (P = 
0.031), but not in breast cancer or colorectal cancer cell 
lines (P = 0.278 and P = 0.423, respectively).
Patient baseline data
A total of 73 patients were included in the study. 
Seventy-one (97%) patients underwent a tumor biopsy 
according to protocol. Fifty-nine patients (81%) started 
treatment with everolimus, of whom 43 (59%) were 
evaluable for efficacy according to TTP ratio and 51 
(70%) for efficacy according to RECIST. Tumor material 
sufficient for sequencing analysis was obtained in 37 
patients (51%) of the TTP cohort and 43 patients (59%) 
of the RECIST cohort (Figure 1). Nine biopsies were 
insufficient for sequencing due to a low or absent tumor 
percentage. Six biopsies were insufficient due to a low 
DNA yield. We obtained sequence data of 1,977 genes 
for 38 patients, and whole exome sequencing data for 
five patients. The sequencing data reached an average 
coverage of 159x. All 43 patients were also sequenced 
on the IonTorrent (panel of 50 genes and custom-made 
primers for mTOR pathway related genes) to validate 
the mutations. Baseline characteristics of the patients are 
described in Table 2.
Tumor mutation and copy number data
We detected on average sixteen somatic mutations 
per patient in the 1,977 gene set (range zero to eighty-six). 
The most frequently mutated genes included TP53 (N = 
24), APC (N = 9), KRAS (N = 9) and PIK3CA (N = 7). In 
addition, we detected copy number gains and amplification 
Table 1: Cell line data
genetic aberration Estimate Std Error t-value Pr(>|t|) sign level
FGFR2_mut -2,014 0,505 -3,989 0,000 ***
CCNE1 gain 0,897 0,242 3,714 0,000 ***
PTEN_mut -0,536 0,192 -2,788 0,005 **
CDKN2A loss -0,307 0,116 -2,645 0,008 **
RB1_mut 0,486 0,198 2,447 0,015 *
CIC_mut 1,324 0,550 2,408 0,016 *
gain_cnaPANCAN384_,ERCC5,ING1,IRS2,TFDP1, 0,523 0,223 2,346 0,019 *
SRGAP3 loss 0,328 0,141 2,334 0,020 *
loss_cnaPANCAN216 0,724 0,313 2,313 0,021 *
HGF_mut 1,408 0,700 2,011 0,045 *
SOX9_mut 1,048 0,544 1,927 0,054 .
genetic aberration Estimate Std Error t-value Pr(>|t|) sign level
PTEN_mut -0,457 0,189 -2,422 0,016 *
PIK3CA_mut -0,384 0,188 -2,044 0,041 *
gain_cnaPANCAN164_,KRAS, 0,285 0,171 1,660 0,097 .
gain_cnaPANCAN395_,AKT1,HSP90AA1,PPP2R5C, 0,411 0,316 1,298 0,195  
loss_cnaPANCAN44_,BMPR1A,FAS,PTEN, -0,208 0,183 -1,137 0,256  
KRAS_mut -0,193 0,195 -0,985 0,325  
TSC1_mut 0,307 0,490 0,627 0,531  
gain_cnaPANCAN129_,MET, 0,092 0,195 0,470 0,639  
EGFR_mut -0,037 0,340 -0,110 0,912  
gain_cnaPANCAN301_,CDK12,ERBB2,MED24, -0,018 0,246 -0,071 0,943  
gain_cnaPANCAN124_,EGFR, 0,010 0,180 0,055 0,956  
Legend: This table illustrates genetic aberrations that could potentially predict sensitivity to mTOR inhibition, based on an in 
vitro drug screen with temsirolimus. Part A of the table demonstrates the relation between genetic aberrations and sensitivity 
to temsirolimus, corrected for tumor type and excluding blood cell tumors. Part B shows similar data, but is analyzed per gene 
and specifically directed at genetic aberrations previously associated with sensitivity to mTOR inhibition.
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of several well-known oncogenes such as ERBB2 (N = 6), 
PIK3CA (N = 4), CCND1 (N = 3), MYC (N = 3), EGFR (N 
= 2), MET (N = 2), MDM2 (N = 2) and KRAS (N = 1), and 
amplification of TERT in 5 samples. Losses were detected 
of SMAD4 and CDKN2A (both N = 8), TP53 (N = 5), APC 
(N = 5), PTEN, VHL and RB1 (all N = 4), and specifically 
TSC1 (N = 3) and TSC2 (N = 1). 
Genomic variations and treatment response in 
patients
When exploring the cell line data, several 
hypotheses were generated with regard to the correlation 
between genomic aberrations and treatment response. 
The first step was to evaluate if these hypotheses could be 
tested in our patient data set. The rest of the paragraph is 
focused on TTP ratio assessment, because only one patient 
had a RECIST response, and because PFS is a longitudinal 
endpoint similar to TTP ratio, but without the correction 
for individual tumor growth rate. 
In vitro data suggested increased resistance to 
mTOR inhibitors in the presence of a gain of CCNE1 or 
mutation in RB1. In our patient data however, all patients 
with a gain of CCNE1 (N = 2) or mutation in RB1 (N = 2) 
had clinical benefit from treatment (defined as TTP ratio 
response) (Table 3, Supplementary Table 1). Mutations in 
Table 2: Baseline characteristics
Demographic or Clinical Characteristic No. of patients % 
No. of patients  43  
Sex 
    Male
 
26
 
60.5
Age, years
    Mean 
    Range 
 
60
31 – 79
WHO PS
    0 
    1 
    2 
    Missing 
 
14
26
1
2
 
32.6
60.5
2.3
4.7 
Primary tumor 
    Colorectal
    NET 
    Esophageal
    Breast
    NSCLC
    Ovarian 
    Renal cell
    Sarcoma   
    Cervical
    Head and Neck
    Bladder 
    Mesothelioma
    Thyroid
    Thymoma
    Gastric
    Pancreatic
    Melanoma
    Unknown origin 
 
12
7
4
3
2
2
2
1
1
1
1
1
1
1
1
1
1
1
 
27.9
16.3
9.3
7.0
4.7
4.7
4.7
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
2.3
No. of previous treatments 
    1 
    2 
    3
  >3
9
5
4
25
20.9
11.6
9.3
58.2
Biopsy characteristics
      Tumor percentage
    - Median
    - SD
DNA yield (ng)
    - Median
    - SD 
 
60
23
1440
2123
Legend: This table contains the baseline characteristics of all patients of whom both molecular and clinical response data was 
available. DNA yield is depicted in nanogram. 
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FGFR2, PTEN and loss of CDKN2A were associated with 
increased sensitivity to mTOR inhibition in vitro. In our 
patient data set, there was only one patient with a loss of 
FGFR2, this patient had a favorable outcome in terms of 
TTP ratio. Loss of CDKN2A (N = 7) was not correlated 
with TTP ratio response (either as a binary outcome or as 
a continuous outcome). Five patients had either a mutation 
or copy number loss of PTEN. Despite the fact that it was 
only possible to generate a TTP ratio for three of these 
patients (which classified them as responders) the other 
two patients also had clinical signs of a treatment effect: 
in one patient, central necrosis of all target lesions was 
observed at first response evaluation whereas the other 
patient had a PFS of 90 weeks, with a TTP1 period of 
23 weeks. This patient was not evaluable for TTP ratio 
analysis, due to loss of volumetric measurability. When 
categorizing these five patients as responders, there was 
a significant correlation between treatment response and 
PTEN status (P = 0.046; one-tailed Fisher’s exact test). 
It should be noted however that these PTEN aberrations 
often coincided with other mTOR pathway related 
mutations (Supplementary Table 1). PIK3CA was also 
associated with increased sensitivity to mTOR inhibition 
in vitro. However, we could not find an association in 
our patient data (seven responders versus three non-
responders). 
Using an unbiased, overall analysis, no other 
somatic mutations or copy number alterations showed a 
significant correlation with response. Similarly, combining 
genetic aberrations or comparing somatic mutations 
on the pathway level did not yield significant results. 
To evaluate if genetic aberrations had a downstream 
effect by activating respectively the mTOR or MAPK 
pathway, we evaluated pS6 and pERK status. However, 
when incorporating pS6 and pERK status in previously 
mentioned analyses, we were still not able to predict 
clinical benefit, nor were pS6 and pERK predictive for 
response as single markers. 
When focusing on mTOR (or interconnected) 
pathway related genes, we observed an equal distribution 
of responders and non-responders in KRAS mutated 
Table 3: Genetic aberrations and response 
Gene Clinical benefit Statistics
 Yes No p value
KRAS 5 5 .327
PIK3CA 7 3 .377
MAPK 5 4 .623
CDKN2A 5 2 .326
PTEN 5 0 .046*
ERBB2 3 2 .625
TSC1 2 2 NA
AKT 2 0 NA
CCNE1 2 0 NA
RB1 2 0 NA
TSC2 1 0 NA
MTOR 1 0 NA
FGFR2 1 0 NA
Legend: This table contains the number of patients that 
have, or have not experienced clinical benefit from 
treatment, stratified per afflicted gene. 
Figure 1 : Evaluability of patients. This figure illustrates the evaluability of patients for the biomarker analyses. A single patient can 
be evaluable according to both RECIST and TTP ratio. Abbreviations: IC, Informed Consent; PD, Progressive Disease. 
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patients. This equal distribution was also observed in 
patients with other MAPK mutated genes. More directly 
upstream of MTOR are TSC1 and TSC2. One breast cancer 
patient harbored a missense TSC1 mutation and indeed 
responded to everolimus. Four tumor samples showed 
copy number loss or a mutation of TSC1 and one tumor 
showed loss of TSC2; these events were evenly divided 
over responders and non-responders. 
Figure 2 : Pre-post treatment biopsy. This figure demonstrates the copy number profile of chromosome 7 in patient #2 pre-treatment 
and post-treatment. Pre-treatment, there is an amplification of MET. This amplification is not present in the post-treatment biopsy. Instead, 
there is an amplification of BRAF wild-type.
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Pre- and post-treatment comparison
Nine patients underwent a post-treatment biopsy 
procedure, of which four biopsies were of sufficient 
quality for DNA sequencing. Two of these patients had 
a TTP ratio response. In patient #1 (breast cancer), no 
resistance mechanisms were detected. Patient #2’s tumor 
initially harbored a very focal, high level amplification of 
the MET proto-oncogene (Figure 2). During treatment this 
amplification was clearly reduced, while a second high 
level gain on chromosome 7 appeared, i.e. affecting BRAF. 
DISCUSSION
In this study, we found that copy number loss or 
mutation of PTEN was associated with treatment benefit 
of everolimus, suggesting that PTEN status could be a 
predictive biomarker for benefit from treatment. PTEN 
was frequently speculated to be a marker of interest, 
however, most clinical biomarker studies did not find a 
significant correlation with response [8, 9, 11, 12, 14, 17, 
18]. This could be a result of the method used to determine 
PTEN status, as many studies used immunohistochemistry 
instead of DNA sequencing. Janku et al. were one of 
the few to combine immunohistochemistry and DNA 
sequencing in their biomarker study and had similar 
findings to our study [14]. Furthermore, this was the first 
study to employ an intra-patient control to determine 
treatment benefit. These findings should be further 
confirmed in other trial designs, such as basket studies. 
Although currently published (pre-)clinical data 
report contradictory results, KRAS and PIK3CA mutation 
status have previously been associated with respectively 
resistance and sensitivity to mTOR inhibition in particular 
tumor types. In our dataset, we did not observe an 
association between mutations in either of these genes 
and treatment response. However, the sample size of this 
study is insufficient to make any statements regarding the 
absence of such an association. 
Interestingly, a new amplification of wild-type BRAF 
was identified in a post-treatment biopsy, suggestive of a 
potential mechanism of resistance to mTOR inhibition. 
This tumor had a pre-treatment MET amplification. 
Both MET and BRAF can activate the MAPK-signaling 
pathway, but while MET functions upstream of mTOR, 
BRAF is just downstream of mTOR/Akt so activation of 
MAPK at this level circumvents the possible effect of 
mTOR inhibition. This data illustrates, that although post-
treatment biopsies are difficult to acquire, they do provide 
hypothesis-generating information. 
While this study yielded interesting findings and 
the data produced will be released to large sequencing 
databases to facilitate data sharing in further biomarker 
discovery efforts, there is an important side note. This 
study was drafted and implemented five years ago, when 
next generation sequencing technology had only just 
found its way to research centers and hospitals worldwide. 
The unprecedented wealth of genetic information fueled 
faith and optimism to identify markers for response 
and select patients for treatment. The past years have 
revealed that the implementation of genomics-based 
personalized medicine is not as simple as initially thought 
[24]. Complicating factors are amongst others varying 
degrees of tumor type dependence for the efficacy of 
biomarker-drug combinations, discrepancies between in 
vitro and in-patient findings, and a lower than expected 
incidence of actionable mutations [24]. In our study, the 
discrepancies between in vitro and in-patient findings can 
also be a result of the use of different mTOR inhibitors. 
Negative results for the first large genotype-matched drug 
trial (SHIVA), where context, i.c. tumor type, dependence 
was not taken into account, have also raised concerns 
[24, 25]. Another major hurdle is, that for many targeted 
agents, there are no established biomarkers. To identify 
single (or combinations of) molecular alterations that 
can predict treatment outcome, other study designs with 
more homogeneous patient groups (basket trials) or large 
cohorts of patients ( > 1000) are necessary [26, 27]. The 
latter can only be achieved by world-wide collaborations 
and sharing of data [28]. National- and worldwide 
sequencing initiatives such as the CPCT or project GENIE 
(by the American Association of Cancer Research) have 
been established to facilitate these efforts [28]. And 
whereas many of these efforts mainly focus on genomics-
based analyses, we should aim to incorporate other types 
of analyses such as transcriptomics or proteomics. 
To conclude, this study identified an association 
between PTEN status and treatment benefit from 
everolimus, identifying PTEN status as a potential 
biomarker for everolimus therapy. BRAF wildtype 
amplification could be a potential mechanism of resistance. 
MATERIALS AND METHODS
Cell line data
Genetic profiles and drug sensitivity measurements 
of cell lines treated with the mTOR inhibitor temsirolimus 
were analyzed for potential biomarkers for treatment. 
This dataset (GDSC1000 v17a) was downloaded from 
http://cancerrxgene.org/gdsc1000/Pharmacogenomic_
interactions.html [29].
Patients
The CPCT-03 study was an open-label, single arm, 
biomarker study. The primary objective was to identify 
genetic predictors for response to mTOR inhibition by 
everolimus. Patients with advanced solid malignancies 
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without regular treatment options were eligible for 
inclusion. Inclusion and exclusion criteria, as well as 
detailed information on everolimus treatment, safety 
assessments and study design have been described 
previously [30]. The protocol was approved by the 
Institutional Review Board of The Netherlands Cancer 
Institute and complied with the Declaration of Helsinki, 
Dutch law and Good Clinical Practice guidelines. All 
patients provided written informed consent prior to 
study-related procedures. Patients were accrued at the 
Netherlands Cancer Institute, UMC Utrecht Cancer 
Center, and Erasmus MC Cancer Institute. The study was 
registered on ClinicalTrials.gov (NCT01566279).
Clinical efficacy assessments
Efficacy was measured according to three endpoints, 
TTP ratio, Response Rate (RR) and Progression-free 
survival (PFS). The TTP ratio uses an intra-patient control 
to correct for natural tumor growth rate and has been 
described previously by Cirkel et al. [30]. 
Tumor biopsy
After inclusion, all patients underwent a pre-
treatment histological tumor biopsy of a metastatic 
lesion. A post-treatment tumor biopsy was optional. 
Biopsies were snap-frozen and stored at -80°C. Safety 
and feasibility of the CPCT ‘biopsy pipeline’ has been 
described by Bins et al. [31]. Blood samples (10mL) were 
collected in K2EDTA tubes, as a reference to determine 
somatic mutations. 
Evaluability
Patients evaluable according to either RECIST or 
TTP ratio were evaluable for biomarker analyses in case 
of an adequate tumor biopsy (tumor percentage ≥30% and 
DNA yield ≥500ng).
DNA sequencing
Histological assessment to confirm the presence of 
tumor cells and mark regions with high tumor cellularity 
for macro-dissection was performed by a pathologist 
(S.W.). DNA was extracted from whole blood and 
macro-dissected tumor sections. Barcoded libraries 
were generated as previously described and enriched 
for a “Cancer mini-genome” of 1,977 cancer genes, 
based on Vermaat et al. and Hoogstraat et al. [32-34]. 
Enriched libraries were sequenced to an average coverage 
of 150x on a SOLiD 5500xl instrument according to 
manufacturer’s protocol. Whole exome sequencing was 
performed for six patients using the NextSeq 500 v2 as 
our sequencing facility switched platforms. Somatic 
mutations were validated with the Ion Ampliseq Cancer 
Panel or custom-made primers for mTOR-related genes. 
Mapping, variant calling and annotation was done as 
previously described [33]. Sam tools mpileup was used 
to ensure the absence or presence of a variant in a given 
sample [35]. Copy number profiles were generated using 
CNVkit [36]. Detailed information on sequencing methods 
and bioinformatics pipelines can be reviewed in online-
only supplementary materials.
Immunohistochemistry
In order to determine activation of mTOR and 
interconnected pathways, all available biopsies (N = 
33) were stained for phospho-S6 and phospho-ERK. 
Phospho-S6 is a marker for activation of mTOR, pERK 
is a marker for MAPK pathway activation. Slides were 
scored for intensity (0-3) and percentage of positive tumor 
cells by a pathologist blinded for treatment outcome. 
Statistical analyses
No formal sample size calculation was performed 
due to an unknown expected RR of a heterogeneous 
group of tumors with unknown frequencies of genetic 
aberrations that might be predictive for response. The 
study was open for accrual of 60 evaluable patients or 
15 evaluable TTP ratio responders. R (version 3.2.1) was 
used for downstream analyses of mutations and copy 
number variation, and to detect associations between 
genetic variation, tumor type and treatment response. All 
genetic aberrations (copy number gain, loss or mutation) 
were encoded as binary variables, where 0 = absence 
and 1 = presence of the mutation. On the cell line data, 
elastic net feature selection was performed using the 
R-package glmnet [37]. We used linear models to assess 
the significance of the presence of (multiple) genetic 
aberrations while correcting for tumor type and ANOVA to 
determine the effect of tissue type on treatment response. 
Univariate analyses of single genes within specified 
tumor types were done using one- or two-tailed t-tests, 
depending on context. If previous data or literature had 
already provided an indication of the direction of the 
effect, a one-tailed test was used. In our patient data, we 
tested associations between single variables and response 
using Fisher’s exact test and associations between multiple 
variables and outcome were modeled using logistic 
regression. We assessed pathway enrichment of genetic 
variation in responders and non-responders as described 
previously [38]. Briefly, we used the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) to define pathways. A 
pathway was considered to be affected if at least one of 
its genes was found mutated. We performed the Fisher’s 
exact test to correlate pathway activation and treatment 
Oncotarget55590www.impactjournals.com/oncotarget
response.
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TERT - Telomerase Reverse Transcriptase
TP53 - Tumor Protein p53
TSC - Tuberous Sclerosis Complex
TTP - Time To Progression 
VHL - Von Hippel-Lindau.
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